<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Verdict for Investors &#187; Wellbrutrin</title>
	<atom:link href="http://www.verdictforinvestors.com/tag/wellbrutrin/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.verdictforinvestors.com</link>
	<description>Predictions You Can Count On</description>
	<lastBuildDate>Wed, 09 Mar 2011 22:18:52 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
		<item>
		<title>Wellbutrin® – Glaxo likely to reverse of Andrx decision</title>
		<link>http://www.verdictforinvestors.com/2003/02/wellbutrin%c2%ae-%e2%80%93-glaxo-likely-to-win-appellate-reversal-of-andrx-decision/</link>
		<comments>http://www.verdictforinvestors.com/2003/02/wellbutrin%c2%ae-%e2%80%93-glaxo-likely-to-win-appellate-reversal-of-andrx-decision/#comments</comments>
		<pubDate>Tue, 04 Feb 2003 20:32:05 +0000</pubDate>
		<dc:creator>Jeff Stewart</dc:creator>
				<category><![CDATA[Patent Infringement Drugs]]></category>
		<category><![CDATA[generic drug suits]]></category>
		<category><![CDATA[Wellbrutrin]]></category>

		<guid isPermaLink="false">http://www.verdictforinvestors.com/?p=37</guid>
		<description><![CDATA[February 4, 2003 INTRODUCTION Andrx’s effort to launch bupropion, a generic version of Wellbutrin (an anti-depressant), is awaiting an appellate decision that will be decided shortly. A Florida federal trial court dismissed Glaxo’s patent infringement suit to block Andrx’s generic Wellbutrin on February 28, 2002. After reading the trial court decision, Verdict predicted that it [...]]]></description>
		<wfw:commentRss>http://www.verdictforinvestors.com/2003/02/wellbutrin%c2%ae-%e2%80%93-glaxo-likely-to-win-appellate-reversal-of-andrx-decision/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Wellbrutrin: Can Glaxo enjoin Andrx during appeal</title>
		<link>http://www.verdictforinvestors.com/2002/02/andrx-wins-summary-judgment-motions-in-wellbrutrin-%e2%80%a6but-this-victory-is-likely-to-be-changed-when-glaxo-appeals%e2%80%a6the-real-issue-is-will-glaxo-be-able-to-enjoin-andrx%e2%80%99s-launch/</link>
		<comments>http://www.verdictforinvestors.com/2002/02/andrx-wins-summary-judgment-motions-in-wellbrutrin-%e2%80%a6but-this-victory-is-likely-to-be-changed-when-glaxo-appeals%e2%80%a6the-real-issue-is-will-glaxo-be-able-to-enjoin-andrx%e2%80%99s-launch/#comments</comments>
		<pubDate>Thu, 28 Feb 2002 20:37:47 +0000</pubDate>
		<dc:creator>Jeff Stewart</dc:creator>
				<category><![CDATA[Patent Infringement Drugs]]></category>
		<category><![CDATA[generic drug suits]]></category>
		<category><![CDATA[Wellbrutrin]]></category>

		<guid isPermaLink="false">http://www.verdictforinvestors.com/?p=39</guid>
		<description><![CDATA[A Florida Federal judge today denied Glaxo’s motion for summary judgment and granted Andrx’s motion for summary judgment stating that “Andrx has effectively designed around” Glaxo’s patent. This is an unexpected[1] win for Andrx and, given Andrx’s stock price recent decline, this decision is likely to boost Andrx’s stock price in the short term. Based [...]]]></description>
		<wfw:commentRss>http://www.verdictforinvestors.com/2002/02/andrx-wins-summary-judgment-motions-in-wellbrutrin-%e2%80%a6but-this-victory-is-likely-to-be-changed-when-glaxo-appeals%e2%80%a6the-real-issue-is-will-glaxo-be-able-to-enjoin-andrx%e2%80%99s-launch/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
